Objective To investigate the efficacy, cycle control and tolerability of a phasic oral
contraceptive containing ethinylestradiol 35/30/30 μg and desogestrel 50/100/150 μg …

Objective: To assess the differences and similarities in efficacy, safety, and metabolic effects
of oral contraceptives (OCs) containing the new progestins desogestrel, gestodene, and …

Objective: To compare ovulation inhibition and ovarian activity with 21-day and 24-day
regimens of a low-dose combined oral contraceptive (COC) containing 60 μg of gestodene …

Efforts to minimize oral contraceptive side effects have focused on the use of new dosage
schemes and the synthesis of new steroids that can be used in safer, low-dose formulations …

The effect of a triphasic oral contraceptive containing ethinyl estradiol and gestodene
(EE/GSD) on various lipid and lipoprotein parameters was compared with that of a …

The study was performed in 14 young women. The combination oral contraceptive
contained 75 μg gestodene (GSD) and 20 μg ethinyl estradiol (EE 2) per dosage unit. The …

The effect of two oral contraceptives containing 30 μg ethinylestradiol+ 75 μg gestodene or
30 μg ethinylestradiol+ 150 μg desogestrel upon various hormonal parameters were …

Two triphasic oral contraceptives containing gestodene (GES)(a new progestogen) and
levonorgestrel (LNG) were compared with respect to contraceptive effect, cycle control …

The aim of the trial was to demonstrate the contraceptive efficacy of a new low dose oral
contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel and to observe …

The efficacy, cycle-control and tolerance of Microgynon-30, a widely prescribed
levonorgestrel containing oral contraceptive, and Femodene, a new oral-contraceptive …